| Literature DB >> 34616506 |
Jia Wang1,2,3, Jingjing Yang1,2,3, Chen Wang4, Zhibai Zhao1,2,3, Yuan Fan1,2,3.
Abstract
BACKGROUND: Oral lichen planus (OLP) is a relatively common chronic inflammatory disease of unknown etiology, which might be caused by oxidative stress and impaired antioxidant defense.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34616506 PMCID: PMC8490066 DOI: 10.1155/2021/9914652
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1PRISMA flow diagram of the study selection process.
Description of the studies comparing oxidative/antioxidative markers in patients with OLP and controls.
| Sample size (males/females) | Age (years; mean ± SD or median [minimum–maximum]) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Author (publication year) | Country | Study | Case | Control | Case | Control | OLP characteristics | Biomarkers of interest | Biological specimen | Quality |
| Abdolsamadi (2014) | Iran | CC | 36 (14/22) | 36 (15/21) | 43.1 ± 9.6 | 40.1 ± 6.1 | Erosive OLP | TAC, MDA, Vit A, Vit E, Vit C | Saliva | 5 |
| Azizi (2012) | Iran | CC | 48 (14/34) | 44 (10/34) | 40.2 ± 4.9 | 42.2 ± 4.9 | Erosive OLP | TAC | Saliva, plasma | 5 |
| Bakhtiari (2017) | Iran | CC | 25 (10/15) | 30 (10/20) | 46 ± 2.33 | 36 ± 1.18 | Reticular ( | UA | Saliva | 3 |
| Bao (2016) | China | CC | 57 (13/44) | 115 (43/72) | 52.47 ± 15.13 | 53.10 ± 15.59 | — | Zn | Serum | 7 |
| Batu (2016) | Turkey | CC | 18 (5/13) | 18 (9/9) | 50.67 ± 12.39 | 49.22 ± 11.11 | Reticular ( | MDA, SA, AOPP | Saliva, serum | 6 |
| Darczuk (2019) | Poland | CC | 40 (20/20) | 40 (20/20) | — | — | Reticular OLP ( | Tyr, UA, GPx | Saliva | 5 |
| Darczuk (2016) | Poland | CC | 62 (30/32) | 30 (10/20) | 42.53 ± 10.69 | 42.12 ± 12.22 | Reticular form of lichen planus ( | GSH, TAC, TBARS | Saliva | 5 |
| Ergun (2011) | Turkey. | CC | 21 (11/10) | 20 (11/9) | 54.7 ± 9.2 | 33.7 ± 6.9 | TAC, MDA, TP | Saliva | 5 | |
| Gholizadeh (2014) | Iran | CS | 44 | 44 | — | — | Erosive, nonerosive | Zinc | Serum | 3 |
| Gupta (2017) | India | CC | 39 (14/25) | 39 (14/25) | — | — | Erosive subtype 43.6%, atrophic 17.9%, plaque-like 7.7%, papular 2.6%, and bullae 2.6% | UA | Serum | 5 |
| Hashemy (2016) | Iran | CC | 25 (8/17) | 23 (7/16) | 46.48 ± 11.08 | 43.70 ± 12.23 | Erosive OLP, keratotic OLP | MDA, TAC | Serum | 8 |
| Kapoor (2013) | India | CC | 25 | 25 | [20–45] | [20–45] | Reticular type of OLP ( | NO | Saliva | 5 |
| Kaur (2016) | Belgium | CC | 40 (20/20) | 40 (20/20) | 49 ± 5.8 | 48.9 ± 7.0 | — | 8-OHdG, MDA, vitamin E, vitamin C | Saliva | 5 |
| Lopez-Jornet (2014) | Spain | CS | 40 (9/31) | 30 (6/24) | 60 ± 12.6 | 57 ± 10.8 | Reticular-papular ( | TAC, MDA | Saliva | 5 |
| Mehdipour (2014) | Iran | CS | 20 | 20 | 34.1 | 35.6 | — | NO | Serum | 3 |
| Nagao (2001) | Japan | CC | 62 (15/47) | 248 (60/188) | 60.6 ± 9.2 | 60.7 ± 9.1 | Reticular ( | Retinol, | Serum | 7 |
| Panjwani (2013) | India | 30 | 30 | — | — | Reticular lichen planus ( | NO | 4 | ||
| Rekha (2017) | India | CS | 30 (13/17) | 30 (15/15) | 42.033 ± 1.57 | 45.17 ± 2.25 | — | SOD, MDA, GPx, UA | Saliva | 6 |
| Shaw (2020) | India | CC | 43 (14/29) | 42 (15/27) | 45.95 ± 15.10 | 44.24 ± 15.47 | — | UA | Saliva, serum | 6 |
| Shirzad (2014) | Iran | CC | 30 (4/26) | 30 (4/26) | 44.37 ± 8.16 | 44.77 ± 8.61 | Erosive ( | TAC, MDA | Saliva | 7 |
| Shiva (2020) | Iran | CC | 22 (10/12) | 22 (9/13) | 48.7 ± 9.2 | 43.7 ± 6.9 | — | NO, CRP | Saliva | 6 |
| NO, CRP | Serum | |||||||||
| Sunitha (2006) | India | CC | 20 (8/12) | 20 (8/12) | 37.7 | 33.4 | — | Nitrite | Saliva | 3 |
| Totan (2015) | Romania | CC | 30 (15/15) | 30 (20/10) | — | — | — | 8-OHdG, MDA, UA, TAC, GPx | Saliva, serum | 6 |
| Tvarijonaviciute (2017) | Spain | CS | 20 (0/20) | 31 (11/20) | 57.5 [37.0–75.0] | 33.0 [18.0–67.0] | — | TEAC1, TEAC2, CUPRAC, FRAP, NO, nitrates, nitrites, TEA, AOOP, ROS | Saliva | 4 |
| Upadhyay (2010) | India | CC | 22 | 15 (8/7) | 47 | 43 | — | Thiol, MDA, TAA | Serum | 3 |
CC = case control; CS = cross-sectional; TAC = total antioxidant capacity; MDA = malondialdehyde; Vit = vitamin; UA = uric acid; Zn = zinc; SA = sialic acid; AOOP = advanced oxidation protein product; GPx = glutathione peroxidase; GSH = glutathione; TBARS = thiobarbituric acid reactive substances; TAC = total antioxidant capacity; TP = total protein; NO = nitric oxide; SOD = superoxide dismutase; CRP=C-reactive protein.
Meta-analyses of comparisons of oxidative/antioxidative markers between OLP patients and controls.
| Effect size (OLP vs. controls) | Heterogeneity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marker (source) | # of studies | OLP, | Control, | SMD (95% CI) | Chi2 | df | ||||
| NO (saliva) | 4 | 97 | 108 | 3.25 (1.11, 5.39) | 2.98 | 86.4 | 3 | 97 | ||
| NO (serum/plasma) | 2 | 42 | 42 | 1.07 (0.60, 1.53) | 4.47 | 1.03 | 1 | 3 | ||
| MDA (saliva) | 9 | 307 | 264 | 2.38 (1.47, 3.29) | 5.13 | 138.81 | 8 | 94 | ||
| MDA (serum/plasma) | 4 | 91 | 83 | 0.92 (0.38, 1.46) | 3.34 | 8.37 | 3 | 64 | ||
| 8-OHdG (saliva) | 2 | 70 | 70 | 3.78 (0.14, 7.42) | 2.04 | 38.24 | 1 | 97 | ||
| AOOP (saliva) | 2 | 39 | 49 | 1.00 (0.54, 1.45) | 4.31 | 0.50 | 1 | 0 | ||
| TAC (saliva) | 7 | 267 | 220 | -2.03 (-3.03, -1.03) | 3.98 | 115.29 | 6 | 95 | ||
| TAC (serum/plasma) | 4 | 121 | 109 | -2.87 (-4.56, -1.19) | 3.34 | 57.84 | 3 | 95 | ||
| Vit C (saliva) | 2 | 76 | 76 | -2.03 (-3.16, -0.89) | 3.5 | 7.87 | 1 | 87 | ||
| UA (saliva) | 5 | 168 | 173 | -2.65 (-4.20, -1.09) | 3.33 | 127.97 | 4 | 97 | ||
| UA (serum/plasma) | 3 | 112 | 111 | -1.19 (-1.83, -0.54) | 3.61 | 9.77 | 2 | 80 | ||
| Vit A (saliva) | 2 | 98 | 284 | -0.86 (-3.24, 1.52) | 0.71 | 54.52 | 1 | 98 | ||
| Zn (serum/plasma) | 2 | 101 | 159 | 0.21 (-1.73, 2.16) | 0.22 | 47.99 | 1 | 98 | ||
| GPx (saliva) | 3 | 100 | 100 | -1.34 (-2.81, 0.13) | 1.78 | 42.02 | 2 | 95 | ||
| Vit E (saliva) | 3 | 138 | 324 | -1.53 (-3.41, 0.34) | 1.60 | 92.75 | 2 | 98 | ||
| Nitrite (saliva) | 2 | 40 | 51 | -0.23 (-2.81, 2.35) | 0.17 | 30.43 | 1 | 97 | ||
TAC = total antioxidant capacity; Vit C = vitamin C; UA = uric acid; NO = nitric oxide; MDA = malondialdehyde; AOOP = advanced oxidation protein product; Vit A = vitamin A; Zn = zinc; GPx = glutathione peroxidase; Vit E = vitamin E.
Figure 2Evidence of increased oxidative stress markers in oral lichen planus (OLP). Forest plots show higher malondialdehyde (MDA) in saliva and serum/plasma and 8-hydroxy-deoxyguanosine (8-OHdG) and advanced oxidation protein product (AOOP) level in saliva from subjects with OLP compared to healthy controls (P < 0.05 for each).
Figure 3Evidence of increased nitrosative stress markers in oral lichen planus (OLP). Forest plots show higher nitric oxide (NO) levels in saliva and serum/plasma from OLP patients compared to healthy controls (P < 0.05 for each).
Figure 4Evidence of decreased antioxidant defenses in oral lichen planus (OLP). Forest plots show lower levels of uric acid (UA) in saliva and plasma/serum and vitamin C in saliva from OLP patients to healthy controls (P < 0.05 for each).
Figure 5Evidence of decreased total redox status in oral lichen planus (OLP). Forest plots show lower levels of total antioxidative capacity (TAC) in saliva and plasma/serum from OLP patients than from healthy individuals (P < 0.05 for each).
Figure 6Bias risk of the included studies.
Subgroup analysis of TAC (saliva).
| Subgroup |
| SMD (95% CI) | ||||
|---|---|---|---|---|---|---|
| Race | Asian | 4 | -2.41 (-3.95, -0.86) | <0.00001 | 98 | 0.42 |
| European | 3 | -1.55 (-2.93, -0.17) | <0.00001 | 98 |
Subgroup analysis of MDA (saliva).
| Subgroup |
| SMD (95% CI) | ||||
|---|---|---|---|---|---|---|
| Race | Asian | 5 | 1.30 (0.76, 1.85) | <0.00001 | 83 | 0.008 |
| European | 4 | 0.92 (0.62, 1.21) | <0.00001 | 100 |
Sensitivity analysis of TAC (saliva) using the method of eliminating literature one by one.
| Deleted article |
| SMD (95% CI) | |
|---|---|---|---|
| Abdolsamadi | 93 | <0.00001 | -1.67 (-2.59, -0.74) |
| Azizi | 95 | <0.00001 | -2.01 (-3.20, -0.81) |
| Darczuk | 96 | <0.00001 | -2.10 (-3.34, -0.87) |
| Ergun | 95 | <0.00001 | -2.33 (-3.39, -1.27) |
| Lopez-Jornet | 93 | <0.00001 | -2.33 (-3.31, -1.35) |
| Shirzad | 95 | <0.00001 | -1.89 (-2.98, -0.80) |
| Totan | 95 | <0.00001 | -1.91 (-3.01, -0.80) |
Sensitivity analysis of MDA (saliva) using the method of eliminating literature one by one.
| Deleted article |
| SMD (95% CI) | |
|---|---|---|---|
| Abdolsamadi | 95 | <0.00001 | 2.54 (1.50, 3.58) |
| Batu | 94 | <0.00001 | 2.61 (1.64, 3.58) |
| Darczuk | 95 | <0.00001 | 2.35 (1.33, 3.37) |
| Ergun | 95 | <0.00001 | 2.58 (1.59, 3.57) |
| Kaur | 90 | <0.00001 | 1.87 (1.18, 2.55) |
| Lopez-Jornet | 94 | <0.00001 | 2.16 (1.26, 3.06) |
| Rekha | 95 | <0.00001 | 2.39 (1.37, 3.42) |
| Shirzad | 95 | <0.00001 | 2.51 (1.47, 3.55) |
| Totan | 95 | <0.00001 | 2.47 (1.43, 3.52) |
Figure 7Schematic representation of the oxidative stress and antioxidant markers in oral lichen planus. Black arrows: markers with statistical differences in meta-analysis. Grey arrows: trend but no statistical differences. Unmarked: reported by a single study. Abbreviations: ROS = reactive oxygen species; RNS = reactive nitrogen species; MDA = malondialdehyde; AOOP = advanced oxidation protein product; 8-OHdG = 8-hydroxy-deoxyguanosine; NO = nitric oxide; GPx = glutathione peroxidase; SOD = superoxide dismutase; UA = uric acid; Vit = vitamin; Zn = zinc; TAC = total antioxidative capacity.